Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $1,737,000.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $17.37, for a total transaction of $1,737,000.00. Following the sale, the insider directly owned 1,412,058 shares of the company’s stock, valued at approximately $24,527,447.46. The trade was a 6.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $17.54 on Friday. The company has a market capitalization of $2.81 billion, a P/E ratio of -53.16 and a beta of 2.15. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $20.76. The business’s 50 day simple moving average is $14.85 and its 200-day simple moving average is $15.59.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same period in the prior year, the company earned ($0.20) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ADPT shares. BTIG Research restated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday. JPMorgan Chase & Co. reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Guggenheim reissued a “buy” rating and set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, TD Cowen raised their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after acquiring an additional 2,914 shares during the period. Caxton Associates LLP bought a new position in Adaptive Biotechnologies in the first quarter valued at about $93,000. New York State Common Retirement Fund boosted its holdings in Adaptive Biotechnologies by 39.2% in the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after acquiring an additional 13,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Adaptive Biotechnologies by 728.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after acquiring an additional 333,379 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.